| Ticker Details |
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
|
| IPO Date: |
December 1, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$435.99M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.72 | 2.31%
|
| Avg Daily Range (30 D): |
$0.20 | 2.31%
|
| Avg Daily Range (90 D): |
$0.20 | 2.13%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
.54M |
| Avg Daily Volume (90 D): |
.68M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
63 |
| Avg Trade Size (Sh.) (90 D): |
62 |
| Institutional Trades |
| Total Institutional Trades: |
5,091 |
| Avg Institutional Trade: |
$2.47M |
| Avg Institutional Trade (30 D): |
$.82M |
| Avg Institutional Trade (90 D): |
$1.2M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.11M |
| Avg Closing Trade (30 D): |
$.81M |
| Avg Closing Trade (90 D): |
$1.01M |
| Avg Closing Volume: |
109.03K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.14
|
$.13
|
$-1.01
|
|
Diluted EPS
|
$-.2
|
$.07
|
$-.96
|
|
Revenue
|
$676.8M
|
$156.1M
|
$148.7M
|
|
Gross Profit
|
$367.1M
|
$84.1M
|
$63.8M
|
|
Net Income / Loss
|
$-8.6M
|
$6.8M
|
$-54.6M
|
|
Operating Income / Loss
|
$60.7M
|
$10.5M
|
$-27.9M
|
|
Cost of Revenue
|
$309.7M
|
$72M
|
$84.9M
|
|
Net Cash Flow
|
$8.7M
|
$-47.6M
|
$-40.1M
|
|
PE Ratio
|
|
|
|
|
|
|
